Disc Medicine Past Earnings Performance
Past criteria checks 0/6
Disc Medicine's earnings have been declining at an average annual rate of -36.9%, while the Biotechs industry saw earnings growing at 15.9% annually.
Key information
-36.9%
Earnings growth rate
37.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -23.8% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How Disc Medicine makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -81 | 25 | 73 |
| 31 Dec 23 | 0 | -76 | 22 | 69 |
| 30 Sep 23 | 0 | -64 | 20 | 57 |
| 30 Jun 23 | 0 | -66 | 18 | 50 |
| 31 Mar 23 | 0 | -60 | 17 | 46 |
| 31 Dec 22 | 0 | -47 | 14 | 33 |
| 30 Sep 22 | 0 | -44 | 11 | 29 |
| 30 Jun 22 | 0 | -37 | 10 | 27 |
| 31 Mar 22 | 0 | -37 | 7 | 26 |
| 31 Dec 21 | 0 | -36 | 6 | 25 |
Quality Earnings: IRON is currently unprofitable.
Growing Profit Margin: IRON is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IRON is unprofitable, and losses have increased over the past 5 years at a rate of 36.9% per year.
Accelerating Growth: Unable to compare IRON's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IRON is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: IRON has a negative Return on Equity (-23.84%), as it is currently unprofitable.